Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
- IRWD reported an adjusted loss of 2 cents per share for Q1 2024. - Total revenues in Q1 were $74.9 million, missing estimates due to Linzess sales. - IRWD revised its 2024 revenue guidance downwards, causing a 17% stock decline. - IRWD is evaluating apraglutide in various studies for potential development and submission. - Shares of IRWD have plunged 41.1% year to date. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
- IRWD reported an adjusted loss of 2 cents per share for Q1 2024.
- Total revenues in Q1 were $74.9 million, missing estimates due to Linzess sales.
- IRWD revised its 2024 revenue guidance downwards, causing a 17% stock decline.
- IRWD is evaluating apraglutide in various studies for potential development and submission.
- Shares of IRWD have plunged 41.1% year to date.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.